Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial
-
Published:2024-08
Issue:
Volume:49
Page:101143
-
ISSN:2666-6065
-
Container-title:The Lancet Regional Health - Western Pacific
-
language:en
-
Short-container-title:The Lancet Regional Health - Western Pacific
Author:
Zhang Fujie,
Wu Hao,
Cai Weiping,
Ma Ping,
Zhao Qingxia,
Wei Hongxia,
Lu Hongzhou,
Wang Hui,
He Shenghua,
Chen Zhu,
Chen YaokaiORCID,
Wang Min,
Wan Wan,
Fu Heliang,
Qin HongORCID
Reference45 articles.
1. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach,2021
2. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel;Gandhi;JAMA,2023
3. Major revision version 11.0 of the European AIDS clinical society guidelines 2021;Ryom;HIV Med,2022
4. Tolerability of current antiretroviral single-tablet regimens;Domingo;AIDS Rev,2018
5. Dolutegravir plus two different prodrugs of tenofovir to treat HIV;Venter;N Engl J Med,2019